| Zoledronic acid | Control | P value |
---|---|---|---|
No. of patients treated | 19 | 21 | Â |
Age (years) | 72.9 ± 4.8 | 73.4 ± 5.2 | 0.75 |
Strategy of ADT | Â | Â | Â |
 First-line therapy | 12 | 16 | 0.37 |
 Salvage therapy | 7 | 5 |  |
T-stage | Â | Â | Â |
 T1c | 1 | 0 | 0.19 |
 T2 | 5 | 2 |  |
 T3 | 12 | 19 |  |
 T4 | 1 | 0 |  |
N-stage | Â | Â | Â |
 N0 | 15 | 18 | 0.59 |
 N1 | 4 | 3 |  |
Gleason score | Â | Â | Â |
 ≤6 | 2 | 3 | 0.25 |
 7 | 5 | 9 |  |
 ≥8 | 12 | 9 |  |
Pretreatment PSA (ng/ml) | 76 ± 159 | 37 ± 72 | 0.33 |
BMD (g/cm2) | 1.235 ± 0.21 | 1.182 ± 0.22 | 0.45 |
T-score | 0.55 ± 2.04 | 0.05 ± 1.91 | 0.46 |
Biomarker of bone turnover | |||
 Serum NTX (nmolBCE/L) | 15.27 ± 4.86 | 16.13 ± 5.30 | 0.62 |
 Serum ICTP (ng/ml) | 4.02 ± 1.71 | 4.40 ± 1.65 | 0.48 |
 Serum BAP (U/L) | 11.57 ± 2.85 | 13.35 ± 4.29 | 0.13 |